Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), a Canada-based clinical-stage company specialising in immunotherapy for oncology, announced on Thursday that it will host a key opinion leader (KOL) webinar to discuss pelareorep in metastatic pancreatic ductal adenocarcinoma (mPDAC) and other gastrointestinal cancers.
The webinar will take place on Tuesday 22 July 2025 at 1:00 p.m. ET.
It will feature KOLs Dirk Arnold, M.D., Ph.D. (Asklepios Tumorzentrum Hamburg), Alexander Eggermont, M.D., Ph.D. (University Medical Center Utrecht), Sanjay Goel, M.D., M.S., FASCO (Rutgers Cancer Institute of New Jersey), and Devalingam Mahalingam, M.D., Ph.D. (Northwestern University), who will join the Oncolytics management team to discuss pelareorep's existing pancreatic clinical data in addition to its potential as an immunotherapy in mPDAC and other gastrointestinal indications.
A live question and answer session will follow a formal presentation and roundtable discussion with the KOLs.
Registration details can be found at https://oncolyticsbiotech.com/
Actuate Therapeutics advances Ewing Sarcoma trial following positive Phase 1 results
Citius Oncology prices USD9.0m public offering
Innovent Biologics' Phase 1 anti-CLDN18.2 ADC (IBI343) results published in Nature Medicine
Varian launches IntelliBlate in Europe, expanding image-guided microwave ablation for cancer care
Imugene announces Azer-cel Phase 1b clinical trial data
CARsgen successfully defends European GPC3 CAR-T patent
IGI and AbbVie enter global licensing agreement for ISB 2001